Viravaxx AG – the Hep B company

Viravaxx is a clinical-stage drug development company dedicated to Hepatitis B vaccine development with a lead vaccine candidate (VVX001) currently in Phase II clinical trials.

  • Interim data as of Q2/2021 confirm that VVX001 induces a preS-specific IgG antibody response in vaccine naïve adults and in chronically infected patients.

  • An abstract presenting above data was recently submitted to the American Association for the Study of Liver Diseases (AASLD) and will be published in the October 2021 time-range.

  • Viravaxx works with a board of international renowned hepatologists including Fabien Zoulim, Patrick Kennedy and Peter Ferenci.


Hepatitis B virus (HBV) is a DNA virus that infects liver cells and can become chronic if the immune system is not able to clear the virus after an acute infection.

Roughly 450 million people worldwide live with chronic HBV, with 1 million deaths due to HBV-related illnesses.

HBV is a major public health burden in China with 73 million infections in 2019. About 80% of patients develop primary liver cancer or cirrhosis due to chronic HBV infection.

Antiviral drugs have been used effectively to control the disease, but cure rates are very low (less than eight percent cured after four years of daily oral antiviral therapy).